Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Repayments (2016)

Integra Lifesciences Holdings (IART) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $166000.0 as the latest value for Q4 2016.

  • Quarterly Long-Term Debt Repayments changed N/A to $166000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $166000.0 through Sep 2017, down 65.91% year-over-year, with the annual reading at $575.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $166000.0 in Q4 2016 for Integra Lifesciences Holdings, up from $164000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.1 million in Q3 2015 to a low of -$370000.0 in Q4 2014.
  • Historically, Long-Term Debt Repayments has averaged $288363.6 across 3 years, with a median of $163000.0 in 2016.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 1598.4% in 2015 and later plummeted 92.28% in 2016.
  • Year by year, Long-Term Debt Repayments stood at -$370000.0 in 2014, then skyrocketed by 673.78% to $2.1 million in 2015, then crashed by 92.18% to $166000.0 in 2016.
  • Business Quant data shows Long-Term Debt Repayments for IART at $166000.0 in Q4 2016, $164000.0 in Q3 2016, and $163000.0 in Q2 2016.